However, the PI3K pathway has several other survival outputs, particularly from AKT [16, 17], that may elicit similar drug synergy between PI3K pathway inhibitors and BCL-2 antagonists in GCB-DLBCL cells. Here, BCL2 is linked to diffuse large B-cell lymphoma.